Who
Terry Vance
Director
Company insider
Files Form 4 as: Director, Enanta Pharmaceuticals.
In numbers
- Trades disclosed
- 20
- Buys
- 2
- Sells
- 1
- Bought
- $240K
- Sold
- $139K
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 20 Mar 2013
- Last trade
- 11 Mar 2026
- Last filed
- 13 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Mar 2026filed 13 Mar 2026 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 11 Mar 2026filed 13 Mar 2026 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 13 Mar 2025filed 14 Mar 2025 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,700 at $0.00 | filing |
| 6 Mar 2024filed 8 Mar 2024 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,700 at $0.00 | filing |
| 13 Dec 2023filed 15 Dec 2023 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $139K15,295 at $9.12 | filing |
| 16 Mar 2023filed 17 Mar 2023 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,800 at $0.00 | filing |
| 16 Mar 2023filed 17 Mar 2023 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $81K5,800 at $14.00 | filing |
| 2 Mar 2023filed 6 Mar 2023 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,800 at $0.00 | filing |
| 3 Mar 2022filed 7 Mar 2022 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 2 Mar 2021filed 4 Mar 2021 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 26 Feb 2020filed 28 Feb 2020 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 28 Feb 2019filed 1 Mar 2019 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 28 Feb 2018filed 5 Mar 2018 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 16 Feb 2017filed 21 Feb 2017 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 12 Feb 2016filed 17 Feb 2016 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $54K2,000 at $27.04 | filing |
| 11 Feb 2016filed 12 Feb 2016 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 19 Feb 2015filed 20 Feb 2015 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 6 Feb 2014filed 10 Feb 2014 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,640 at $0.00 | filing |
| 26 Mar 2013filed 28 Mar 2013 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $186K13,295 at $14.00 | filing |
| 20 Mar 2013filed 22 Mar 2013 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,800 at $0.00 | filing |
News
Comparing Amphastar Pharmaceuticals (NASDAQ:AMPH) & Enanta Pharmaceuticals (NASDAQ:ENTA)ENTA · tickerreport.com · 13 Oct 2026Contrasting Enanta Pharmaceuticals (NASDAQ:ENTA) and Scilex (NASDAQ:SCLX)ENTA · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Terry Vance; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.